BROMAZEPAM

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H10BrN3O
Molecular Weight	316.153
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

BrC1=CC=C2NC(=O)CN=C(C3=CC=CC=N3)C2=C1

InChI

InChIKey=VMIYHDSEFNYJSL-UHFFFAOYSA-N

InChI=1S/C14H10BrN3O/c15-9-4-5-11-10(7-9)14(17-8-13(19)18-11)12-3-1-2-6-16-12/h1-7H,8H2,(H,18,19)

HIDE SMILES / InChI

Description
Sources: http://www.rochecanada.com/content/dam/roche_canada/en_CA/documents/Research/ClinicalTrialsForms/Products/ConsumerInformation/MonographsandPublicAdvisories/Lectopam/Lectopam_PM_E.pdf
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB01558 | https://www.ncbi.nlm.nih.gov/pubmed/639854 | https://www.ncbi.nlm.nih.gov/pubmed/6124947 | https://www.ncbi.nlm.nih.gov/pubmed/2570451 | https://www.ncbi.nlm.nih.gov/pubmed/24241181

Bromazepam (marketed under several brand names, including Lectopam, Lexotan, Lexilium, Lexaurin, Brazepam, Rekotnil, and Lexotanil)[1] is a benzodiazepine derivative drug, patented by Roche in 1963 and developed clinically in the 1970s. It is mainly an anti-anxiety agent with similar side effects to diazepam (Valium). In addition to being used to treat anxiety or panic states, bromazepam may be used as a premedicant prior to minor surgery. Bromazepam typically comes in doses of 3 mg and 6 mg tablets.[5] Bromazepam is contraindicated and should be used with caution in women who are pregnant, the elderly, patients with a history of alcohol or other substance abuse disorders and children. Prolonged use of bromazepam causes tolerance and may lead to both physical and psychological dependence on the drug, and as a result, it is a medication which is controlled by international law. Bromazepam binds to the GABA receptor GABAA, causing a conformational change and increasing the inhibitory effects of GABA. Bromazepam is a long-acting benzodiazepine and is lipophilic and metabolized hepatically via oxidative pathways.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
GABA-A receptor; anion channel 203 Target ID: CHEMBL1907607 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24241181	Agonist 2752		45.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Anxiety 275 Sources: http://www.rochecanada.com/content/dam/roche_canada/en_CA/documents/Research/ClinicalTrialsForms/Products/ConsumerInformation/MonographsandPublicAdvisories/Lectopam/Lectopam_PM_E.pdf	Primary		Approved 8583	LECTOPAM Approved Use Unknown

C_max

Value	Dose	Analyte	Population
88 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/112268_1124020C1045_2_16A_1F.pdf#page=18 \| https://pubmed.ncbi.nlm.nih.gov/2882883/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	BROMAZEPAM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
72 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2882883/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	BROMAZEPAM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
126 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2882883/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	BROMAZEPAM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
139 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2882883/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	BROMAZEPAM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
259 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/112268_1124020C1045_2_16A_1F.pdf#page=18 \| https://pubmed.ncbi.nlm.nih.gov/2273442/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	BROMAZEPAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
169 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/112268_1124020C1045_2_16A_1F.pdf#page=18 \| https://pubmed.ncbi.nlm.nih.gov/2273442/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	BROMAZEPAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
0.131 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/112268_1124020C1045_2_16A_1F.pdf#page=18 \| https://pubmed.ncbi.nlm.nih.gov/5586/	12 mg single, oral dose: 12 mg route of administration: Oral experiment type: SINGLE co-administered:	BROMAZEPAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
43.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14517708/	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	BROMAZEPAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

AUC

Value	Dose	Analyte	Population
1844 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/112268_1124020C1045_2_16A_1F.pdf#page=18 \| https://pubmed.ncbi.nlm.nih.gov/2273442/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	BROMAZEPAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1233 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/112268_1124020C1045_2_16A_1F.pdf#page=18 \| https://pubmed.ncbi.nlm.nih.gov/2273442/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	BROMAZEPAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
2.99 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/112268_1124020C1045_2_16A_1F.pdf#page=18 \| https://pubmed.ncbi.nlm.nih.gov/5586/	12 mg single, oral dose: 12 mg route of administration: Oral experiment type: SINGLE co-administered:	BROMAZEPAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1328 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14517708/	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	BROMAZEPAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

T_1/2

Value	Dose	Analyte	Population
20.4 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/112268_1124020C1045_2_16A_1F.pdf#page=18 \| https://pubmed.ncbi.nlm.nih.gov/2882883/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	BROMAZEPAM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
28.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2882883/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	BROMAZEPAM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
32.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2882883/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	BROMAZEPAM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
28.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2882883/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	BROMAZEPAM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
32.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14517708/	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	BROMAZEPAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

F_unbound

Value	Dose	Analyte	Population
28.4% OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/112268_1124020C1045_2_16A_1F.pdf#page=18 \| https://pubmed.ncbi.nlm.nih.gov/2882883/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	BROMAZEPAM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
29.4% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2882883/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	BROMAZEPAM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
34.2% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2882883/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	BROMAZEPAM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
35.5% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2882883/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	BROMAZEPAM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
29.9% EXPERIMENT https://www.info.pmda.go.jp/go/interview/2/112268_1124020C1045_2_16A_1F.pdf#page=19		BROMAZEPAM plasma	Homo sapiens

Doses

Dose	Population	Adverse events
180 mg single, oral Overdose Dose: 180 mg Route: oral Route: single Dose: 180 mg Sources: https://pubmed.ncbi.nlm.nih.gov/20040343/	unknown, ADULT Health Status: unknown Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/20040343/	Disc. AE: Coma... AEs leading to discontinuation/dose reduction: Coma (1 pt) Sources: https://pubmed.ncbi.nlm.nih.gov/20040343/
220 mg 1 times / day multiple, oral Overdose Dose: 220 mg, 1 times / day Route: oral Route: multiple Dose: 220 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27663828/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/27663828/	Other AEs: cognitive impairment, falls... Other AEs: cognitive impairment (1 pt) falls (1 pt) dependence (1 pt) tolerance (1 pt) Sources: https://pubmed.ncbi.nlm.nih.gov/27663828/
9 mg 3 times / day steady-state, oral Overdose Dose: 9 mg, 3 times / day Route: oral Route: steady-state Dose: 9 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1292648/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/1292648/	Other AEs: dystonia... Other AEs: dystonia (1 pt) Sources: https://pubmed.ncbi.nlm.nih.gov/1292648/
1.5 mg 2 times / day steady-state, oral Recommended Dose: 1.5 mg, 2 times / day Route: oral Route: steady-state Dose: 1.5 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2571196/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2571196/	Sources: https://pubmed.ncbi.nlm.nih.gov/2571196/
6 mg 1 times / day steady-state, oral Recommended Dose: 6 mg, 1 times / day Route: oral Route: steady-state Dose: 6 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/20667143/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/20667143/	Other AEs: Gastritis... Other AEs: Gastritis (1 pt) Sources: https://pubmed.ncbi.nlm.nih.gov/20667143/
5 mg 3 times / day steady-state, oral Studied dose Dose: 5 mg, 3 times / day Route: oral Route: steady-state Dose: 5 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/237849/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/237849/	Sources: https://pubmed.ncbi.nlm.nih.gov/237849/

AEs

AE	Significance	Dose	Population
Coma	1 pt Disc. AE	180 mg single, oral Overdose Dose: 180 mg Route: oral Route: single Dose: 180 mg Sources: https://pubmed.ncbi.nlm.nih.gov/20040343/	unknown, ADULT Health Status: unknown Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/20040343/
cognitive impairment	1 pt	220 mg 1 times / day multiple, oral Overdose Dose: 220 mg, 1 times / day Route: oral Route: multiple Dose: 220 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27663828/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/27663828/
dependence	1 pt	220 mg 1 times / day multiple, oral Overdose Dose: 220 mg, 1 times / day Route: oral Route: multiple Dose: 220 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27663828/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/27663828/
falls	1 pt	220 mg 1 times / day multiple, oral Overdose Dose: 220 mg, 1 times / day Route: oral Route: multiple Dose: 220 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27663828/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/27663828/
tolerance	1 pt	220 mg 1 times / day multiple, oral Overdose Dose: 220 mg, 1 times / day Route: oral Route: multiple Dose: 220 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27663828/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/27663828/
dystonia	1 pt	9 mg 3 times / day steady-state, oral Overdose Dose: 9 mg, 3 times / day Route: oral Route: steady-state Dose: 9 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1292648/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/1292648/
Gastritis	1 pt	6 mg 1 times / day steady-state, oral Recommended Dose: 6 mg, 1 times / day Route: oral Route: steady-state Dose: 6 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/20667143/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/20667143/

PubMed

Title	Date	PubMed
The role of liquid chromatography-tandem mass spectrometry (LC-MS/MS) to test blood and urine samples for the toxicological investigation of drug-facilitated crimes.	2008-04	18367985
Design and evaluation of a multi-detection system composed of ultraviolet, evaporative light scattering and inductively coupled plasma mass spectrometry detection for the analysis of pharmaceuticals by liquid chromatography.	2008-03-21	18262535
Thiodicarb and methomyl tissue distribution in a fatal multiple compounds poisoning.	2008-03	18366586
Radiofrequency ablation of osseous metastases for the palliation of pain.	2008-03	18030464
Prevalence and sociodemographic characteristics associated with benzodiazepines use among community dwelling older adults: the Bambuí Health and Aging Study (BHAS).	2008-03	17992360
Flurazepam inhibits the P-glycoprotein transport function: an insight to revert multidrug-resistance phenotype.	2008-02-26	18190907
Opioid receptors are involved in the sedative and antinociceptive effects of hesperidin as well as in its potentiation with benzodiazepines.	2008-02-12	18048026
Quetiapine: another drug with potential for misuse? A case report.	2008-01	18312052
Determination of benzodiazepines in oral fluid using LC-MS-MS.	2007-12-21	18093420
The effects of bromazepam on the early stage of visual information processing (P100).	2007-12	18094853
How useful are prescribing indicators based on the DU90% method to distinguish the quality of prescribing between pharmacotherapy audit meetings with different levels of functioning?	2007-12	17909774
[Drug-facilitated crime and sexual abuse: a pediatric observation].	2007-11	17916427
Modeling gene expression regulatory networks with the sparse vector autoregressive model.	2007-08-30	17761000
Development of a validated HPLC method for the determination of four 1,4-benzodiazepines in human biological fluids.	2007-03	17461106
Influence of bromazepam on cortical interhemispheric coherence.	2007-03	17420832
Drug screening of preserved oral fluid by liquid chromatography-tandem mass spectrometry.	2007-02	17158196
[Treatment of hydroxychloroquine poisoning with extracorporeal circulation].	2007-02	17092685
Development and validation of a high performance liquid chromatographic method for the determination of oxcarbazepine and its main metabolites in human plasma and cerebrospinal fluid and its application to pharmacokinetic study.	2007-01-17	16959463
Separation of 1,4-benzodiazepines by micellar elektrokinetic capillary chromatography.	2007-01-10	16563516
[Fixed drug eruption : about 13 cases].	2007-01	17424708
Sensitivity of P-glycoprotein tryptophan residues to benzodiazepines and ATP interaction.	2007-01	16919386
Interactions between iron(III)-hydroxide polymaltose complex and commonly used medications / laboratory studies in rats.	2007	17691586
Endocannabinoid system and synaptic plasticity: implications for emotional responses.	2007	17641734
Hyponatremia-induced seizure during carbamazepine treatment.	2007	17366352
[Drug-related toxic events in the state of São Paulo, Brazil].	2006-12	17173163
Quantification of benzodiazepines in whole blood and serum.	2006-11	16220317
Neuromodulatory effect of bromazepam on motor learning: an electroencephalographic approach.	2006-10-23	16959410
[Effects of bromazepam on motor learning: an electroencephalogram analysis based on the beta rhythm].	2006-10-13	17033984
[The effects of bromazepam on contingent negative variation and reaction time in a visuomotor task].	2006-09-29	17006858
[Appropriate use of benzodiazepines zolpidem and zopiclone in diseases attended in primary care].	2006-09-02	16945275
Anxiolytics, hypnotics, and antidepressants dispensed to adolescents in a French region in 2002.	2006-07	16700077
[Procedural learning and anxiolytic effects: electroencephalographic, motor and attentional measures].	2006-06	16917623
Benzodiazepines prescription in Dakar: a study about prescribing habits and knowledge in general practitioners, neurologists and psychiatrists.	2006-06	16671957
Fast gas chromatography-negative-ion chemical ionization mass spectrometry with microscale volume sample preparation for the determination of benzodiazepines and alpha-hydroxy metabolites, zaleplon and zopiclone in whole blood.	2006-06	16645997
[Neuromodulatory effects of bromazepam when individuals were exposed to a motor learning task: quantitative electroencephalography (qEEG)].	2006-03	16622565
Tension-type headache with aura.	2006-03	16472346
Anti-conflict effects of benzodiazepines in rhesus monkeys: relationship with therapeutic doses in humans and role of GABAA receptors.	2006-01	16378217
Double-blind, comparative study of cyamemazine vs. bromazepam in the benzodiazepine withdrawal syndrome.	2006-01	16243418
Pharmacotherapy of social anxiety disorder: what does the evidence tell us?	2006	17092192
Screening method for benzodiazepines and hypnotics in hair at pg/mg level by liquid chromatography-mass spectrometry/mass spectrometry.	2005-10-15	16154525
On-line solid-phase extraction coupled with high-performance liquid chromatography and tandem mass spectrometry (SPE-HPLC-MS-MS) for quantification of bromazepam in human plasma: an automated method for bioequivalence studies.	2005-10	16175133
Comparison of CZE, MEKC, MEEKC and non-aqueous capillary electrophoresis for the determination of impurities in bromazepam.	2005-09-01	15935599
[Trends in the pharmaceutical profile of intentional drug overdoses seen in the emergency room].	2005-07-02	16097205
Benzodiazepine prescribing behaviour and attitudes: a survey among general practitioners practicing in northern Thailand.	2005-06-23	15975145
Screening and confirmatory method for benzodiazepines and hypnotics in oral fluid by LC-MS/MS.	2005-06-10	15944062
The neuropsychiatry of Parkinson's disease.	2005-06	16175159
Analysis of the influence of bromazepam on cognitive performance through the visual evoked potential (P300).	2005-06	16100968
[Effects of Bromazepam in qEEG by type writing].	2005-06	16059597
[Electroencephalography measures in motor skill learning and effects of bromazepam].	2005-06	16059596
[Neuromodulatory effects of caffeine and bromazepam on visual event-related potential (P300): a comparative study].	2005-06	16059590

Patents

Sample Use Guides

In Vivo Use Guide

Adults: Depending upon severity of symptoms- 6 mg to 18 mg, in equally divided doses. Treatment may be initiated at a lower dose. Elderly: Maximum of 3 mg in equally divided doses. Dose can be increased gradually as needed and tolerated.

Route of Administration: Oral

In Vitro Use Guide

500mkl of this P2-suspension (corresponding to 10mg original brain tissue) was preincubated for 5 min with Bromazepam. 25 mkl of 3H-diazepam working solution (to give a final concentration of 1.9 X 10^-9 M or approximately 14,000 cpm) was then added and the incubation continued for an additional 15 min at 37°C. The samples were then cooled in an ice bath for 30 min. IC50 values, i.e. values for 50% inhibition of specific 3H-diazepam binding, were assessed with at least 3 and up to 7 concentrations of the Bromazepam in duplicate or triplicate.

Name

Type

Language

BROMAZEPAM

Official Name

English

LECTOPAM

Preferred Name

English

RO 5-3350

Code

English

RO-5-3350

Code

English

BROMAZEPAM [USAN]

Common Name

English

LEXOTANIL

Brand Name

English

BROMAZEPAM CIV [USP-RS]

Common Name

English

2H-1,4-BENZODIAZEPIN-2-ONE, 7-BROMO-1,3-DIHYDRO-5-(2-PYRIDINYL)-

Systematic Name

English

LEXOTAN

Brand Name

English

bromazepam [INN]

Common Name

English

BROMAZEPAM [MART.]

Common Name

English

LEXATIN

Brand Name

English

7-Bromo-1,3-dihydro-5-(2-pyridyl)-2H-1,4-benzodiazepin-2-one

Systematic Name

English

BROMAZEPAM [EP MONOGRAPH]

Common Name

English

BROMAZEPAM CIV

Common Name

English

NSC-140669

Code

English

BROMAZEPAM [JAN]

Common Name

English

Bromazepam [WHO-DD]

Common Name

English

BROMAZEPAM [MI]

Common Name

English

Classification Tree Code System Code

DEA NO.

2748